G
Guest
Because of reports of valve thrombosis, a recommendation against the use of enoxaparin (Lovenox) in women with prosthetic heart valves has been added to the warnings section of the labeling for this drug. Information on serious maternal and fetal effects of warfarin have been added to the Precautions section. In a clinical study, clots developed in two of the seven pregnant women who received enoxaparin 1 mg/kg twice a day to reduce the risk of thromboembolism; the two women and their fetuses died. Congenital anomalies have developed in infants born to women who received enoxaparin during pregnancy. Pregnant women and women of childbearing age should be warned of the potential hazards of enoxaparin therapy during pregnancy. Am J Health-syst Pharm 2002;59:606.
